
The panel closes with practical changes clinicians can adopt immediately, including routine risk assessment, attention to the right heart, collaboration with expert centers, and an optimistic message for patients.

Vallerie McLaughlin, MD, is a professor of medicine and director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan.

The panel closes with practical changes clinicians can adopt immediately, including routine risk assessment, attention to the right heart, collaboration with expert centers, and an optimistic message for patients.

Echo findings can point toward precapillary or left heart physiology, but real patients often fall between categories. The panel debates integrated assessment versus choosing a lane for treatment.

New agents across established pathways are in development, while late diagnosis and underrepresented subgroups remain challenges. The panel also cautions that elevated hemodynamics alone do not make a diagnosis of PAH.

Regimen complexity, side effects, and unrealistic expectations drive nonadherence. The panel describes how open conversations, specialty pharmacy partnerships, and attention to quality of life support persistence.

Side effects overlap with disease symptoms and vary widely between patients. The panel outlines how education, careful titration, patient portals, and dedicated nurses and pharmacists help patients stay on therapy.

Patients want their pumps removed, but safety comes first. The panel discusses selection criteria, a rapid parenteral-to-oral transition experience, and practical dosing of oral prostacyclin pathway therapy.

A fourth pathway has delivered notable benefit in heavily pretreated patients, yet parenteral prostacyclin remains lifesaving for the sickest. The panel weighs trial evidence, side effects, and how these drugs work in concert.

Patients who feel well may still need more therapy. The panel discusses setting expectations at diagnosis, weighing a switch against adding a third pathway, and framing treatment around long-term survival.

Risk scores can mislead in older patients with comorbidities and in young patients with enlarged right ventricles. The panel shows why right heart function, not the echo pressure estimate, should anchor follow-up.

Longitudinal follow-up, symptoms, exercise capacity, biomarkers, and echocardiography all contribute to judging response. The panel explains why right ventricular assessment adds precision to serial noninvasive risk scores.

Confirming that a referred patient truly has PAH comes before any treatment change. The panel reviews diagnostic pitfalls, management of patients arriving on monotherapy, and the education needs of newly diagnosed patients.

A single daily tablet now covers two of four treatment pathways. The panel discusses candidate selection, tolerability-driven sequencing, access, and how simplifying therapy makes later escalation easier for patients to accept.

Upfront dual oral therapy is the standard for most non-high-risk patients, supported by landmark morbidity and mortality data. The panel reviews how guidelines have simplified risk-based decisions and why follow-up matters more than the first prescription.

PAH rarely belongs to a single specialty. The panel describes the team-based model behind effective care and reviews how four complementary treatment pathways now give clinicians a broad toolbox.

Intermediate- and high-risk status signals a struggling right ventricle and a prognosis the panel considers unacceptable. They argue for treating risk assessment as a routine vital sign while weighing what patients say they want from therapy.

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.